Search results
Results From The WOW.Com Content Network
Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines. . Released in beta in November 2004, the Google Scholar index includes peer-reviewed online academic journals and books, conference papers, theses and dissertations, preprints, abstracts, technical reports, and other ...
Mainly physics and mathematics, but also other. An alternative to arXiv. Well-known for also having many unorthodox papers and also fringe science. >10,000 2009 Scientific God Inc. Wellcome Open Research: Multidisciplinary: At least one of the authors must be a Wellcome researcher >100 2017 Wellcome Trust: WikiJournal Preprints: Multidisciplinary
The term 'inhibitor' is often used in a general sense to describe any compound used to prevent unwanted polymerisation, however these compounds are often divided into 'retarders' and 'true inhibitors'. A true inhibitor has a well defined induction period during which no noticeable polymerisation takes place. They are consumed during this period ...
Scientific Data on PI3K/mTOR Inhibitor VS-5584 Published in Molecular Cancer Therapeutics CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Verastem, Inc., (NAS: VSTM) , a clinical-stage biopharmaceutical ...
In the follow-up literature, comparing research units or even the output of publishing companies became the target of research. [17] [20] White et al. wrote, Libcitation counts reflect judgments by librarians on the usefulness of publications for their various audiences of readers.
Light stabilizer are used to inhibit polymer photo-oxidation, which is the combined result of the action of light and oxygen. Like autoxidation this is a free radical process, hence the antioxidants described above are effective inhibiting agents, however additional classes of additives are also beneficial, such as UV absorbers, quenchers of ...
Monomethyl auristatin E is an antimitotic agent which inhibits cell division by blocking the polymerisation of tubulin.The linker to the monoclonal antibody is stable in extracellular fluid, but is cleaved by cathepsin once the conjugate has entered a tumor cell, thus activating the antimitotic mechanism.
Defactinib (INN, codenamed VS-6063) is an inhibitor of PTK2, also known as focal adhesion kinase (FAK), Pyk2, and MELK which was developed by Pfizer and licensed to Verastem Oncology as a potential treatment for solid tumors. Development for mesothelioma was discontinued in 2015 due to lack of efficacy in a placebo-controlled phase II trial.